Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

por Isla, Dolores, Massuti, Bartomeu, Lázaro, Martín, de Alda, Lucía Ruiz, Gordo, Rocio, Ortega-Joaquín, Nuria, Oyagüez, Itziar
Publicado 2020

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

por Isla, Dolores, De Castro, Javier, Juan, Oscar, Grau, Santiago, Orofino, Javier, Gordo, Rocío, Rubio-Terrés, Carlos, Rubio-Rodríguez, Darío
Publicado 2016

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

por Majem, Margarita, Álvarez, Rosa, Ortega, Ana Laura, Ruiz de Alda, Lucía, Gordo, Rocío, García, J Francisco, Ivanova-Markova, Yoana, González-Domínguez, Almudena, San Cristóbal, Raquel Sánchez, Rojo, Federico
Publicado 2022

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

por Bernabé-Caro, Reyes, Garrido, Pilar, García-Campelo, Rosario, Palmero, Ramón, Artal, Ángel, Bayona, Cristina, Rodríguez-Abreu, Delvys, López-Brea, Marta, Paredes, Alfredo, Vicente, David, Sánchez Torres, José Miguel, Majem, Margarita, Diz, Pilar, Gordo, Rocío, Coca, Margarita, de Castro, Javier
Publicado 2022